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Oxidized LDL stimulates the expression of TGF- and fibronectin in
human glomerular epithelial cells. Abnormal lipid accumulation in gb-
meruli is a recognized early event in the development of glomeruloscle-
rosis. The presence of LDL and scavenger receptors has recently been
demonstrated in glomerular cells, including the visceral epithelial cells. To
explore the possible molecular mechanisms of lipid-induced glomerular
injury, the present investigation was conducted to examine the effects of
oxidized LDL (ox-LDL) on the expression of transforming growth factor
(TGF)-jI and fibronectin by cultured human glomerubar epithelial cells
(GEC). Cultured GEC were exposed to human ox-LDL (0 to 100 rg/ml)
for various time points. Ox-LDL induced a dose- and time-dependent
increase in the expression of TGF-13 mRNA. Actinomycin D, a transcrip-
tional inhibitor, but not cycboheximide, a protein synthesis inhibitor,
inhibited the response. GEC exposed to ox-LDL also demonstrated
elevated levels of fibronectin mRNA. In addition, treatment of GEC with
ox-LDL resulted in increased TGF-13 and fibronectin protein expression as
detected by immunoeytochemistry. Addition of anti-TGF-f3 antibody
significantly inhibited the increase in fibroneetin message level induced by
ox-LDL. These data suggest that ox-LDL stimulates matrix protein
fibronectin in GEC by a mechanism involving expression of TGF-/3. Thus,
accumulation of lipids in human glomerular epithelial cells may contribute
to the pathogenesis of glomeruloselerosis through TGF-13 mediated
mechanism(s).
Hyperlipidemia and lipoprotein abnormalities are associated
with a variety of clinical and experimental renal diseases [1, 2]. In
patients with the nephrotic syndrome, total serum cholesterol,
triglycerides, phospholipids as well as apolipoprotein (apo) B, C,
and E are elevated [31 Qualitative alterations include an in-
creased cholesterol-to-triglyceride ratio and increased cholesterol
content both in very low density lipoprotein (VLDL) and low
density lipoprotein (LDL) [4, 5]. Abnormal lipid deposition is
found in glomeruli with different lesions [6, 7]. In experimental
models, hypercholesterolemia is also associated with glomerular
lipid deposition and glomerulosclerosis [8—10]. Nephrotic animals
fed a cholesterol-supplemented diet had much more profound
morphologic injury, as evidenced by a higher percentage of
glomerulosclerosis [111. In addition, administration of lipid-low-
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ering drugs to nephrotic animals ameliorated the adverse effects
of hypercholesterolemia on glomerular structure and function
[12—14]. Glomerular lipid deposits in rats contain mainly choles-
terol and to a lesser extent triglycerides [8]. Analysis of renal
tissue from experimental nephrotic animals revealed the accumu-
lation of lipids in the mesangium and other glomerular cell types
[15, 16]. Studies using immunohistochemical and immunoelee-
tromicroscopical techniques revealed increased apo E immunore-
activity in glomerular visceral epithelial cells [101. In tissues from
several types of human glomerular diseases, apo B and E were
distributed in droplets within glomerular epithelial cells [17, 18].
Recent investigations have shown that human glomerular mes-
angial and epithelial cells express receptors for LDL [17, 19—21].
Scavenger receptors [22], which can mediate the uptake of
oxidized LDL, were detected in human glomerular cells by
immunohistological studies [17]. This receptor-mediated binding
and uptake of LDL was also found in rat mesangial cells [23, 24].
Furthermore, rat mesangial cells were reported to preferentially
bind and take up oxidized LDL compared to LDL [25]. The
accumulation of lipoproteins in glomerular cells may initiate a
chronic inflammatory reaction and alter cell functions. Addition
of LDL to mesangial cell cultures resulted in alterations in cell
proliferation, prostaglandin synthesis, expression of growth fac-
tors and cytokines, and extracellular matrix protein production
[25—30].
Transforming growth factor (TGF)-J3, a multifunctional growth
cytokine, has been implicated in the pathogenesis of glomerulo-
sclerosis in vivo and in the modulation of the production of
extracellular matrix proteins by glomerular mesangial cells and
epithelial cells in vitro [31—34]. In glomeruli from hypercholester-
olemic nephrotic animals increased fibronectin expression is
associated with increased TGF- expression [35]. LDL stimulates
the expression of TGF-p mRNA in cultured mesangial cells [36].
The increased TGF-f3 bioactivity by mesangial cells exposed to
LDL has been associated with enhanced fibronectin synthesis [28].
Glomerular epithelial cells are one of the major cell types of the
glomerulus. They are a direct target of high concentrations of
lipoproteins during nephrosis [21]. Both LDL and oxidized LDL
receptors are documented on their surface membranes [17].
Human GEC exhibit receptor-mediated uptake of LDL and
intermediate density lipoproteins [21]. However, the effects of
lipoproteins on their functions, especially in regard to growth
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factor production and a fibrogenic mechanism have not been fully
explored. To date there are no data published on the expression
of TGF-/3 by human GEC. The present study was designed to
examine the effects of lipoproteins on the expression of TGF-13
and fibronectin in cultured human GEC, and to evaluate the effect
of lipoprotein-induced TGF-/3 on expression of this matrix protein
message.
Methods
Human glomerular epithelial cell culture
Human kidney tissue was obtained from macroscopically nor-
mal areas of nephrectomy specimens from renal tumor patients.
Glomeruli were isolated by differential sieving of minced cortices,
collagenase digested and plated, as previously described [37].
Early cellular outgrowths at 8 to 14 days were removed by
trypsinization, filtered, and then repiated. Glomerular epithelial
cells were identified by their characteristic polygonal appearance
as seen on phase-contrast microscopy, sensitivity to puromycin
aminonucleoside, and staining for heparan sulfate proteoglycan
and vimentin, but not for myosin, actin or factor VIII on
immunofluorescence [38, 39].
Although it is not possible to determine specifically whether
GEC in culture originate from visceral or parietal epithelium by
current criteria [40, 41], we believe that the cells originating from
decapsulated giomeruli after sieving, are most likely of visceral
origin [391.
Human GEC (from 2 donors) were used between passages 5
and 9 and were maintained in Duibecco's minimal essential
medium (DMEM; Sigma Chemical Co., St. Louis, MO, USA),
supplemented with 10% heat-inactivated fetal bovine serum
(FBS; GIBCO, Grand Island, New York, USA), 100 U/mI peni-
cillin, 100 g/ml streptomycin, 2 mrvi L-glutamine, 15 mrvi Hepes,
5 j.rg/mi insulin, 5 pg/mi transferrin and 5 pg/mi selenium (ITS;
Collaborative Biomedical Products, Bedford, MA, USA) at 37°C
in a humidified atmosphere of 5% CO2 and 95% air. The cells
were grown in 100 mm petri dishes (Becton Dickinson, Franklin
Lakes, NJ, USA) until subconfiuence was reached.
Experimental treatments of GEC
Prior to all experiments GEC were placed in 5% Nu-Serum (a
defined serum substitute containing 25% FBS, Collaborative
Research) for 48 hours to provide a relatively lipoprotein deficient
environment and to maximize lipoprotein receptor activity [42].
Then, cultures were exposed to various concentrations of native
LDL and ox-LDL for the indicated times. LDL and ox-LDL were
obtained from Biomedical Technologies Inc. (Stoughton, MA,
USA). As supplied, LDL was isolated from human plasma and
purified via ultracentrifugation to homogeneity as determined by
agarose gel electrophoresis. The preparations contained negligi-
ble thioharbituric acid-reactive moieties (TBARS) as determined
by using a calorimetric assay for malondialdehyde (MDA). Ox-
LDL was prepared using the oxidant Cu2SO4. The TBARS value
of ox-LDL was 19.3 nM of MDA/mg protein. In separate experi-
ments, GEC were incubated with ox-LDL in the presence of
rabbit anti-human TGF-f3 antibody or nonspecific rabbit IgG
(R&D Systems, Minneapolis, MN, USA) for 6 and 24 hours. The
cultures were also treated with either actinomycin D (5 .tg/ml),
cycloheximide (10 pg/ml; both from Sigma), ox-LDL (50 /.Lg/ml)
and actinomycin (5 pg/mi), or ox-LDL (50 jig/mI) and cyclohex-
imide (10 jig/ml).
Cell viability was determined by microscopic evaluation and by
exclusion of trypan blue (Sigma). All treated-cells appeared to be
healthy and there was no observable adverse effects on cellular
morphology and trypan blue exclusion (> 95%).
RNA preparation and analysis
After treatment of the cells for the indicated times, total
cellular RNA was extracted by the acid guanidinium thiocyanate
phenol chloroform method [3I• RNA concentrations were deter-
mined using spectrophotometric absorbance at 260 nm. Fifteen
jig RNA samples in ethidium bromide (1 jig/mI) were electro-
phoresed on a 1.2% agarose gel containing 0.66 M formaldehyde
and subsequently blotted onto NYTRAN nylon membranes
(Schleicher & Schuell, Keene, NH, USA) by capillary transfer.
RNA was immobolized by baking 80°C for 30 minutes. The blots
were examined under ultraviolet illumination to determine the
position of the 28 s and 18 s ribosomal RNA bands and to assess
the integrity of RNA. The blot was then sandwiched between two
pieces of Schleicher & Schuell 589-WH qualitative filter paper
and hybridized in a plastic bag in a solution containing 1 M NaCl,
0.05 M Tris-HC1, pH 7.4, 10% dextran sulfate, 1% sodium dodecyl
sulfate, and 0.1 mglml salmon sperm DNA with addition of a
human oligonucleotide probe for TGF-J31 (Oncogene Science,
Inc., Uniondale, NY, USA), a human fibronectin eDNA probe
(GIBCO BRL), and a human GAPDH eDNA probe (Clontech,
Palo Alto, CA, USA) as a reference probe to allow for corrections
in differences in RNA sample loading. The oligonucleotide probe
was end-labeled with [32P]-ATP and T4 polynucleotide kinase
(Boehringer Mannheim, Indianapolis, IN, USA). The eDNA
probes were labeled with [32"]-dCTP, using a random-primed
eDNA labeling kit (Boehringer Mannheim). After hybridization
at 65°C for 20 hours, blots were washed twice in 2 X SSC-0.1%
SDS at 25°C for 20 minutes and once in 2 x SSC-0.1% SDS at
65°C for 30 minutes. The blots were then exposed to Kodak X-O
MAT film with enhancing screens at —70°C to develop autora-
diograms. The quantitative densitometry was performed on auto-
radiographs with a computer-based measurement system. The
mRNA levels for TGF-pl and fibronectin were expressed as a
ratio of the optical density units for either TGF-131 or fibronectin
to GAPDH.
Immunohistochemical labeling
GEC grown on glass coverslips were exposed to ox-LDL (50
j.tg/ml) for 24 hours. Immunoperoxidase staining was performed
using the avidin-biotin complex method as previously described
[44]. GEC on coverslips were rinsed three times with ice-cold
phosphate-buffered saline (PBS), pH 7.4, and fixed with 100%
methanol for 5 to 7 minutes at —20°C. The fixed coverslips were
rinsed three times with PBS, and then incubated with 1.5%
normal goat serum for 20 minutes at 25°C, followed by incubation
with primary antibodies, either rabbit polyclonal anti-human
TGF-13 antibody (1:250; R&D Systems) or rabbit polyclonal
anti-human fibronectin (1:500; Chemicon International Inc., Te-
mecula, CA, USA) for 60 minutes at 25°C. After removing
unbound primary antibody and rinsing with PBS, coverslips were
incubated with biotinylated goat anti-rabbit IgG (1:200; Vector
Laboratories, Burlingame, CA, USA) for 60 minutes at 25°C.
we..,
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Coverslips were rinsed and then incubated with avidin-biotiny-
lated horseradish peroxidase (Vectastain Elite ABC Kit; Vector)
for 30 minutes at 25°C, followed by incubation (5 mm at 25°C)
with 0.1% diaminobenzidine tetrahydro-chioride (Sigma) in 0.1
mol/liter Tris buffer, pH 7.6, containing 0.02% H202. Finally,
coverslips were washed in tap water and mounted with Per-
mount® (Fisher Scientific, Pittsburg, PA, USA). Negative controls
consisted of substituting the primary antibody with nonspecific
rabbit IgG or PBS.
Analytical studies
Results were expressed as means SE for three separate
experiments. Statistical analysis were performed using Student's
t-test with P < 0.05 taken as significant.
Results
Effect of ox-LDL on TGF-(3 mRNA expression in GEC
The effect of increasing concentrations of ox-LDL on TGF-/3
gene expression in GEC during 12 hours incubation is shown in
Figure 1. Untreated cells express TGF- mRNA in low steady-
state levels, whereas GEC treated with ox-LDL exhibited in-
creased expression of TGF-13 mRNA in a concentration-depen-
dent manner between 25 and 100 xg/ml (113 + 14%, 151 10%,
180 6%, and 195 22% of control for ox-LDL 25, 50, 75, and
100 jig/mI, respectively). We then evaluated the time course
during which ox-LDL could affect TGF-p gene expression. As
shown in Figure 2, ox-LDL (50 jig/mI) increased steady-state
TGF-/3 mRNA levels. Up-regulated expression appeared at six
hours (210 74% of control), and remained elevated at nine
hours (163 16% of control, P < 0.05) and 12 hours (217 56%
of control). At 24 hours, the TGF-/3 message was still elevated
(285 66% of control, P < 0.05).
In comparison with ox-LDL, incubation of GEC with native
LDL led to the TGF-/3 message increase in a less pronouced
dose-dependent fashion between 25 and 150 jig/mi (105 2%,
120 9%, 155 18%, and 157 44% of control for native LDL
25, 50, 100, and 150 jig/mI, respectively). Native LDL (100
jxg/ml)-induced TGF- /3 mRNA increase appeared at three hours
(126 9% of control, P < 0.05) and peaked at 12 hours (145
8% of control, P < 0.05). At 24 hours, the message level was
139 27% of control. There was little or no difference in TGF-/3
message levels of GEC cultured between time 0 and 24 hours in
the absence of native LDL or ox-LDL (data not shown). Since
ox-LDL was more potent in stimulation of TGF-/3 mRNA expres-
sion, all the subsequent experiments was carried out with ox-LDL.
Effect of ox-LDL on fibronectin mRNA levels in GEC
In the next series of experiments, the effect of ox-LDL on
fibronectin message expression was assessed. GEC fibronectin
mRNA levels were determined in cells cultured in the presence of
ox-LDL (50 jig/mI). As shown in Figure 3, GEC constitutively
expressed fibronectin-specific mRNA. An increase in fibronectin
message was seen at 6 to 24 hours treatment with ox-LDL. The
maximum stimulatory effect was observed at 24 hours post-
treatment (325 33% of control, P < 0.05).
Ox-LDL-stimulated TGF-p and fibronectin protein expression by
immunocytochemisriy
Since ox-LDL stimulated TGF-/3 and fibronectin mRNA ex-
pression in GEC, we evaluated the effects of ox-LDL on TGF-/3
and fibronectin protein production in GEC treated with or
without ox-LDL (50 jig/mi). As shown in Figure 4, faint staining
for TGF-f3 and fibronectin proteins were seen in untreated cells
(Fig. 4 A, A'). Exposure to ox-LDL increased the intensity of
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Fig. 1. Dose response of TGF-i3 mRNA expression from ox-LDL-treated
human glomerular epithelial cells (GEC). Northern blotting analysis of total
RNA from control GEC (lane 1) and GEC treated with different
concentrations of ox-LDL for 12 hours: 25 jig/mI (lane 2), 50 jig/mI (lane
3), 75 jig/mI (lane 4), and 100 jig/ml (lane 5). Blots were probed for
TGF-1 (A) and then for GAPDH (B). C shows 28 s and 18 s rRNA. D.
quantitative expression of TGF-/31 mRNA abundance after correcting for
the GAPDH signal. The TGF-/3 mRNA levels of treated GEC are
expressed as % increases above the mRNA levels of untreated controls.
Values are presented as the mean se of three separate experiments.
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Fig. 2. Time course of TGF-f3 mRNA expression from ox-LDL-treated
GEC. Northern blotting analysis of total RNA from the control cells (lane
1) and cells treated with ox-LDL (50 pg/mI) for three hours (lane 2), six
hours (lane 3), nine hours (lane 4), 12 hours (lane 5), and 24 hours (lane
6). Blots were probed for TGF-1 (A) and GAPDH (B). C. Quantitative
expression of TGF-131 mRNA abundance after correcting for the GAPDH
signal. Data are expressed as described in Figure 1 legend. *P < 0.05
versus control (representative of 3 separate experiments).
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Fig. 3. Expression of fibronectin (FN) mRNA from ox-LDL-treated GEC.
Northern blotting analysis of total RNA from GEC controls (lane 1 from
0 hr control and lane 7 from 24 hr control) and GEC treated with ox-LDL
(50 pg/mI) for three hours (lane 2), six hours (lane 3), nine hours (lane 4),
12 hours (lane 5), and 24 hours (lane 6). Blots were probed for FN (A) and
then for GAPDH (B). C. Quantitative expression of FN mRNA abun-
dance after correcting for the GAPDH signal. Data are expressed as
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staining for TGF-/3 (Fig. 4B) and fibronectin (Fig. 4B'). The
enhanced fibronectin positivity appears to be cell associated. This
may be related to the fact that the cells have been exposed to
ox-LDL for relatively brief periods of time. Negative controls did
not show increased staining (data not shown).
Effect of anti-TGF-[3 antibody on ox-LDL-stimulated expression of
fibronectin mR/VA
To investigate whether the newly-produced TGF-/3 was in-
volved in the ox-LDL-stimulated fibronectin gene expression,
GEC were incubated with ox-LDL (50 xg/ml) in the presence of
rabbit anti-human TGF-J3 antibody (30 pg/mi) or non-specific
rabbit IgG (30 jig/mI) for 6 and 24 hours. The fibronectin-specific
mRNA was then analyzed by Northern hybridization. As shown in
Figure 5, the addition of anti-TGF-/3 antibody for 24 hours
significantly down-regulated fibronectin message expression in
GEC treated with ox-LDL (139 24% in ox-LDL+ anti-TGF-p
vs. 217 31% in ox-LDL, P < 0.05). In contrast, the addition of
control rabbit IgG did not blunt ox-LDL-stimulated fibronectin
mRNA expression (241 35% in ox-LDL+ normal IgG vs. 217
31% in ox-LDL). GEC co-treated with anti-TGF-f3 antibody and
ox-LDL for six hours also exhibited a decrease in the mRNA level
(96 7% in ox-LDL + anti-TGF-f3 vs. 112 6% in ox-LDL) (not
shown).
Effects of inhibitors of gene transcription and protein synthesis on
ox-LDL-stimulated TGF-/3 mRNA expression
GEC were co-treated with ox-LDL and the transcriptional
inhibitor, actinomycin D (AMD,5 j.tg/ml), to determine whether
transcriptional events are involved in the increase in TGF-/3
mRNA induced by ox-LDL. As seen in Figure 6, actinomycin D
inhibited the ox-LDL-stimulated increase in TGF-/3 mRNA (ox-
LDL+ AMD, 43 7.0% of control, N 3).
To assess the possible role of new protein synthesis in the action
of ox-LDL, GEC were treated with ox-LDL and cycloheximide
(CHX, 10 jxg/mL), a protein synthesis inhibitor. When GEC were
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Fig. 4. Immunoperoxidase staining of human
GECfor TGF-f3 (A, B) and fibronectin (A', B').
A and A' are the cells not exposed to ox-LDL.
B and B' are the cells exposed to ox-LDL (50
rgIml) for 24 hours. TGF-13 (B) and fibronectin
(B') were obviously increased in GEC exposed
to ox-LDL. Comparable results were obtained
in three sets of experiments.
fibronectin mRNA was observed (201 26%, P < 0.05). On the
other hand, treatment of GEC with cycloheximide in the presence
of ox-LDL further increased TGF-p mRNA levels (ox-LDL +
CHX, 303 48% of control, N = 3).
Discussion
The pathogenic roles of atherogenic lipoproteins and glomer-
ular cell alterations in structure and function have prompted
investigations aimed at understanding the pathogenesis of ii-
poprotein-mediated glomerular injury. The present study shows
that both ox-LDL and native LDL can stimulate TGF-/3 mRNA
expression in cultured human GEC. Stimulation of GEC with
ox-LDL caused an increase in TGF-J3 protein production as
detected by immunocytochemistry. To our knowledge, the current
investigation is the first demonstration that cultured glomerular
epithelial cells express TGF-f3, which appears to be a unique
growth factor in its ability to stimulate glomerular extracellular
matrix protein (ECM) production and deposition, ultimately
leading to glomerulosclerosis [311.
Glomerular visceral epithelial cells are one of the major cell
types within the glomerulus and play an important role in
maintaining normal structure and function of the glomerular
basement membrane (GBM). Significant changes in GEC mor-
phology are frequently found in human and experimental glomer-
ular diseases, particularly in the proteinuric state [51• GEC
proliferation in vivo has been observed in glomerular diseases
such as focal and segmental glomerulosclerosis [461 and passive
Heyman nephritis [47]. During nephrosis, GEC are directly
exposed to increased concentrations of lipoproteins filtered
through the Bowman's capsule.
Accumulation of lipids in GEC has been previously reported
[10, 17, 18]. GrOne et al [91 recently demonstrated receptor-
mediated uptake of LDL by cultured human GEC. Scavenger
receptors, which can mediate the uptake of ox-LDL, are also
present on the plasma membranes of human GEC as detected by
immunocytochemical techniques [17], hut their biological activity
was not tested. Our current investigation demonstrates that both
ox-LDL and native LDL stimulate TGF- gene expression in
human GEC. Ox-LDL is more potent than native LDL. The
reason for this difference is not clear, but may be related to the
state of oxidation of lipoproteins and/or quantitative differences in
the activity of these two types of receptors. Recent investigations
of Wheeler et al [27] revealed that incubation of LDL in culture
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Fig. 5. Effect of anti-TGF-f3 antibody on ox-LDL-stimulated expression of
fibronectin mRNA. Northern blotting analysis of total RNA from GEC
control and GEC treated with ox-LDL in the absence or presence of
anti-TGF-/3 antibody or non-specific rabbit lgG. Blots were probed for
fibronectin (A). Intact 28 s andl8 s rRNA bands are shown by ethidium
bromide staining of agarose gel (B). C. Quantitative expression of FN
mRNA levels as a ratio of the density reading of FN mRNA to that of the
density of rRNA (28 s or 18 s) photograph from ethidium bromide stained
formaldehyde gel. *D < 0.05 versus control. +P < 0.05 versus ox-LDL-
treated (representative of three separate experiments).
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Fig. 6. Effects of actinomycin D and cycloheximide on ox-LDL -stimulated
TGF-j3 mRNA expression. GEC were treated for 12 hours with actinomycin
D (AMD) (5 xgIml) or cycloheximide (CHX) (10 jgIml), in the presence
or absence of ox-LDL (50 xg/ml). Total RNA was extracted for Northern
blotting analysis as described in the methods and Figure 5 legend

































1.0 nM MDA/mg LDL protein although cultured human GEC did
not oxidize LDL up to 24 hours exposure. It is appealing to
speculate that the less apparent response to native LDL may be
mediated by a fraction that has been oxidized during the incuba-
tion. Studies of Coritsidis et a! [25] have shown that rat mesangial
cells preferentially bind and take up ox-LDL. Whether glomerular
epithelial cells possess similar functioning receptors for ox-LDL
remains to be clarified. However, our results are consistent with
those reported for the effects of native LDL and ox-LDL on
platelet-derived growth factor (PDGF) gene expression by
smooth muscle cells [48], renin release by juxtaglomerular cells
[49], and eicosanoid production by mesangial cells [25, 27].
Our studies also show that the ox-LDL-stimulated increase in
the TGF-13 transcript was diminished by actinomycin D, an
inhibitor of gene transcription, suggesting that ox-LDL induces
TGF-13 mRNA synthesis at the transcriptional level. When GEC
were co-treated with ox-LDL and cycloheximide, TGF-f3 mRNA
levels were further increased when compared to GEC treated with
ox-LDL alone. In addition, cycloheximide by itself increased
TGF-/3 transcript levels. The mechanisms by which cycloheximide
affects TGF-j3 mRNA are not known and were not addressed by
the present work. However, the so-called "superinduction" of
mRNA has been described previously in a variety of cell systems
[50]. The mRNA superinduction is usually attributed to decreased
mRNA turnover rate, or alternatively due to the lack of de novo
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synthesis of transcriptional activator inhibitor, such as NF-KB
inhibitor as demonstrated in the pulmonary epithelial cells [51].
TGF-/3 is a multifunctional growth factor that can either inhibit
or stimulate cell proliferation and differention. This growth factor
is generally considered to be the fibrogenic cytokine since it exerts
a marked effects on ECM production [31]. The stimulatory effects
of TGF-[3 on ECM accumulation have been shown in viva by
transfer of the TGF-13 gene into the rat kidney [52].
An apparent relationship between increased renal TGF-f3
expression and ECM expansion has been demonstrated in various
experimental and human glomerulopathies [31, 35, 53]. Resident
glomerular cells possess high-affinity receptors for TGF-p and
produce TGF-/3 [32, 541. Previous studies in glomerular epithelial
cells in vitro have shown that TGF-13 is able to increase the
production of several matrix proteins [34]. Exposure of GEC to
TGF-p, in addition to up-regulating the synthesis of proteogly-
cans, increased the production of fibronectin, type IV collagen,
and laminin. It has been suggested that GEC may be the cell type
contributing the fibronectin and other nonproteoglycan compo-
nents to the TGF-13-incuced ECM expansion in experimental
glomerulonephritis [34]. The fact that GEC exposed to ox-LDL
produces TGF-f3, combined with the presence of high-affinity
receptors for TGF-p on the cell surfaces of GEC strongly suggest
that important interactions may occur in these cell types. In our
GEC culture system, we subsequently evaluated the effects of
ox-LDL on fibronectin expression. Ox-LDL increased the gene
expression of fibronectin after six hours of treatment. The maxi-
mum stimulatory effect was found at 24 hours post-treatment. The
increased protein synthesis of fibronectin was also demonstrated
immunohistochemically. We further hypothesized that the newly-
produced TGF-f3 in response to ox-LDL stimulates fibronectin
expression. When GEC were exposed to ox-LDL in the presence
of neutralizing antibody to TGF-/3, we noticed an obvious reduc-
tion in fibronectin mRNA levels. These data support our hypoth-
eses that ox-LDL stimulates the production of TGF-13, and that
the newly-produced TGF-p is involved in increased fibronectin
expression. Studies in glomerular mesangial cells revealed that
LDL also stimulates fibronectin gene expression and protein
synthesis [29]. LDL-stimulated fibronectin protein synthesis was
completely blocked by the neutralizing antibody to TGF-/3 [28].
Although these in vitro experiments show a role for lipoprotein-
induced growth factor production and fibronectin synthesis, the
relevance of these findings to events that occur in vivo remains to
be clarified. In renal diseases, such as focal glomerulosclerosis,
apo B-containing lipoproteins were demonstrated in the visceral
epithelial cells [17]. The in vivo deposition of lipoproteins may
have effects similar to that of ox-LDL or LDL on human GEC in
vitro.
In summary, the present study shows that ox-LDL stimulates
the gene expression and protein production of TGF-13 and
fibronectin in cultured human GEC. The released TGF-f3 appears
to be involved in the regulation of fibronectin expression in an
autocrine fashion. Our data suggest that GEC is a potential source
for the fibrogenic growth factor, TGF-/3. Thus, the production of
TGF-f3 by GEC may have important implications in the develop-
ment of glomerulosclerosis.
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